Chemotherapy decisions and patient experience with the recurrence score assay for early-stage breast cancer
详细信息 查看全文
- 作者：Christopher R. Friese ; Yun Li ; Irina Bondarenko ; Timothy P. Hofer ; Kevin C. Ward ; Ann S. Hamilton ; Dennis Deapen ; Allison W. Kurian and Steven J. Katz
- 刊名：Cancer
- 出版年：2017
- 出版时间：January 1, 2017
- 年：2017
- 卷：123
- 期：1
- 页码：43-51
- 全文大小：345K
- ISSN：1097-0142
文摘
The 21-gene recurrence score (RS) assay stratifies early-stage, estrogen receptor–positive breast cancer by recurrence risk. Few studies have examined the ways in which physicians use the RS to recommend adjuvant systemic chemotherapy or patients' experiences with testing and decision making.